{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T14:33:49Z","timestamp":1790087629207,"version":"4.0.1"},"reference-count":58,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,10,28]],"date-time":"2022-10-28T00:00:00Z","timestamp":1666915200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Cardiovasc. Med."],"abstract":"<jats:p>\n                    Bempedoic acid is a new cholesterol-lowering drug, which has recently received US FDA and EMA approval. This drug targets lipid and glucose metabolism as well as inflammation\n                    <jats:italic>via<\/jats:italic>\n                    downregulation of ATP-citrate lyase and upregulation of AMP-activated protein kinase (AMPK). The primary effect is the reduction of cholesterol synthesis in the liver and its administration is generally not associated to unwanted muscle effects. Suppression of hepatic fatty acid synthesis leads to decreased triglycerides and, possibly, improved non-alcoholic fatty liver disease. Bempedoic acid may decrease gluconeogenesis leading to improved insulin sensitivity, glucose metabolism, and metabolic syndrome. The anti-inflammatory action of bempedoic acid is mainly achieved\n                    <jats:italic>via<\/jats:italic>\n                    activation of AMPK pathway in the immune cells, leading to decreased plasma levels of C-reactive protein. Effects of bempedoic acid on atherosclerotic cardiovascular disease, type 2 diabetes and chronic liver disease have been assessed in randomized clinical trials but require further confirmation. Safety clinical trials in phase III indicate that bempedoic acid administration is generally well-tolerated in combination with statins, ezetimibe, or proprotein convertase subtilisin\/kexin type 9 (PCSK9) inhibitors to achieve low-density lipoprotein cholesterol targets. The aim of this narrative review on bempedoic acid is to explore the underlying mechanisms of action and potential clinical targets, present existing evidence from clinical trials, and describe practical management of patients.\n                  <\/jats:p>","DOI":"10.3389\/fcvm.2022.1028355","type":"journal-article","created":{"date-parts":[[2022,10,28]],"date-time":"2022-10-28T02:02:27Z","timestamp":1666922547000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":68,"title":["Mechanism of action and therapeutic use of bempedoic acid in atherosclerosis and metabolic syndrome"],"prefix":"10.3389","volume":"9","author":[{"given":"Gianni","family":"Biolo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pierandrea","family":"Vinci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandro","family":"Mangogna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matteo","family":"Landolfo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paolo","family":"Schincariol","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicola","family":"Fiotti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Filippo","family":"Mearelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Filippo Giorgio","family":"Di Girolamo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2022,10,28]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1016\/j.atherosclerosis.2019.08.014","article-title":"2019 ESC\/EAS guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk.","volume":"290","year":"2019","journal-title":"Atherosclerosis."},{"key":"B2","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1093\/eurheartj\/ehz455","article-title":"2019 ESC\/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk.","volume":"41","author":"Mach","year":"2020","journal-title":"Eur Heart J."},{"key":"B3","doi-asserted-by":"publisher","first-page":"S1","DOI":"10.1016\/j.jacc.2012.11.002","article-title":"The worldwide environment of cardiovascular disease: prevalence, diagnosis, therapy, and policy issues: a report from the American College of Cardiology.","volume":"60","author":"Laslett","year":"2012","journal-title":"J Am Coll Cardiol."},{"key":"B4","doi-asserted-by":"publisher","first-page":"1713","DOI":"10.1016\/S0140-6736(21)01122-3","article-title":"Global perspective of familial hypercholesterolaemia: a cross-sectional study from the EAS familial hypercholesterolaemia studies collaboration (FHSC).","volume":"398","year":"2021","journal-title":"Lancet."},{"key":"B5","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1016\/j.ijcard.2021.10.024","article-title":"LDL cholesterol target achievement in heterozygous familial hypercholesterolemia patients according to 2019 ESC\/EAS lipid guidelines: implications for newer lipid-lowering treatments.","volume":"345","author":"Rizos","year":"2021","journal-title":"Int J Cardiol."},{"key":"B6","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1080\/00015385.2022.2030568","article-title":"Lipid-lowering therapy and risk-based LDL-C goal attainment in Belgium: DA VINCI observational study.","author":"van de Borne","year":"2022","journal-title":"Acta Cardiol."},{"key":"B7","doi-asserted-by":"publisher","first-page":"666","DOI":"10.1016\/j.mayocp.2018.01.011","article-title":"Reinitiation of statin therapy after discontinuation: a meta-analysis.","volume":"93","author":"Ofori-Asenso","year":"2018","journal-title":"Mayo Clin Proc."},{"key":"B8","doi-asserted-by":"publisher","first-page":"11687","DOI":"10.3390\/ijms222111687","article-title":"Statin-associated myopathy: emphasis on mechanisms and targeted therapy.","volume":"22","author":"Vinci","year":"2021","journal-title":"Int J Mol Sci."},{"key":"B9","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1111\/joim.13219","article-title":"Reported muscle symptoms during statin treatment amongst Italian dyslipidaemic patients in the real-life setting: the PROSISA Study.","volume":"290","author":"Casula","year":"2021","journal-title":"J Intern Med."},{"key":"B10","doi-asserted-by":"publisher","first-page":"1206","DOI":"10.1016\/s0026-0495(97)90218-3","article-title":"Lovastatin increases exercise-induced skeletal muscle injury.","volume":"46","author":"Thompson","year":"1997","journal-title":"Metabolism."},{"key":"B11","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1016\/j.amjcard.2011.08.045","article-title":"Effect of statins on creatine kinase levels before and after a marathon run.","volume":"109","author":"Parker","year":"2012","journal-title":"Am J Cardiol."},{"key":"B12","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1016\/j.nut.2017.05.003","article-title":"Higher protein intake is associated with improved muscle strength in elite senior athletes.","volume":"42","author":"Di Girolamo","year":"2017","journal-title":"Nutrition."},{"key":"B13","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1097\/MCO.0000000000000527","article-title":"Contraction and nutrition interaction promotes anabolism in cachectic muscle.","volume":"22","author":"Di Girolamo","year":"2019","journal-title":"Curr Opin Clin Nutr Metab Care."},{"key":"B14","doi-asserted-by":"publisher","first-page":"633987","DOI":"10.3389\/fnut.2021.633987","article-title":"The aging muscle in experimental bed rest: a systematic review and meta-analysis.","volume":"8","author":"Di Girolamo","year":"2021","journal-title":"Front Nutr."},{"key":"B15","doi-asserted-by":"publisher","first-page":"619","DOI":"10.1007\/s11883-022-01036-4","article-title":"Major concepts in treatment with bempedoic acid and inclisiran that clinicians need to know.","volume":"24","author":"Parham","year":"2022","journal-title":"Curr Atheroscler Rep."},{"key":"B16","doi-asserted-by":"publisher","first-page":"839","DOI":"10.3390\/ph15070839","article-title":"New therapeutic approaches in treatment of dyslipidaemia-a narrative review.","volume":"15","author":"Mercep","year":"2022","journal-title":"Pharmaceuticals."},{"key":"B17","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1194\/jlr.M030528","article-title":"AMP-activated protein kinase and ATP-citrate lyase are two distinct molecular targets for ETC-1002, a novel small molecule regulator of lipid and carbohydrate metabolism.","volume":"54","author":"Pinkosky","year":"2013","journal-title":"J Lipid Res."},{"key":"B18","doi-asserted-by":"publisher","first-page":"13457","DOI":"10.1038\/ncomms13457","article-title":"Liver-specific ATP-citrate lyase inhibition by bempedoic acid decreases LDL-C and attenuates atherosclerosis.","volume":"7","author":"Pinkosky","year":"2016","journal-title":"Nat Commun."},{"key":"B19","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1097\/MOL.0000000000000565","article-title":"Bempedoic acid: effects on lipoprotein metabolism and atherosclerosis.","volume":"30","author":"Burke","year":"2019","journal-title":"Curr Opin Lipidol."},{"key":"B20","doi-asserted-by":"publisher","first-page":"1033","DOI":"10.1056\/NEJMoa1806747","article-title":"Mendelian randomization study of ACLY and cardiovascular disease.","volume":"380","author":"Ference","year":"2019","journal-title":"N Engl J Med."},{"key":"B21","doi-asserted-by":"publisher","first-page":"919","DOI":"10.1016\/j.cmet.2022.05.004","article-title":"Inhibition of ATP-citrate lyase improves NASH, liver fibrosis, and dyslipidemia.","volume":"34","author":"Morrow","year":"2022","journal-title":"Cell Metab."},{"key":"B22","doi-asserted-by":"publisher","first-page":"2866","DOI":"10.1194\/jlr.M041590","article-title":"Polymorphisms, de novo lipogenesis, and plasma triglyceride response following fish oil supplementation.","volume":"54","author":"Bouchard-Mercier","year":"2013","journal-title":"J Lipid Res."},{"key":"B23","doi-asserted-by":"publisher","first-page":"647","DOI":"10.1161\/ATVBAHA.116.308963","article-title":"Prevention of diet-induced metabolic dysregulation, inflammation, and atherosclerosis in ldlr(\u2013\/\u2013) mice by treatment with the ATP-citrate lyase inhibitor bempedoic acid.","volume":"37","author":"Samsoondar","year":"2017","journal-title":"Arterioscler Thromb Vasc Biol."},{"key":"B24","doi-asserted-by":"publisher","first-page":"2095","DOI":"10.1194\/jlr.M035212","article-title":"ETC-1002 Regulates immune response, leukocyte homing, and adipose tissue inflammation via LKB1-dependent activation of macrophage AMPK.","volume":"54","author":"Filippov","year":"2013","journal-title":"J Lipid Res."},{"key":"B25","doi-asserted-by":"publisher","first-page":"1095","DOI":"10.1016\/j.molmed.2021.09.004","article-title":"The multifaceted therapeutic value of targeting ATP-citrate lyase in atherosclerosis.","volume":"27","author":"Verberk","year":"2021","journal-title":"Trends Mol Med."},{"key":"B26","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1016\/j.jacl.2015.03.003","article-title":"Use of ETC-1002 to treat hypercholesterolemia in patients with statin intolerance.","volume":"9","author":"Thompson","year":"2015","journal-title":"J Clin Lipidol."},{"key":"B27","doi-asserted-by":"publisher","first-page":"556","DOI":"10.1016\/j.jacl.2015.12.025","article-title":"Treatment with ETC-1002 alone and in combination with ezetimibe lowers LDL cholesterol in hypercholesterolemic patients with or without statin intolerance.","volume":"10","author":"Thompson","year":"2016","journal-title":"J Clin Lipidol."},{"key":"B28","doi-asserted-by":"publisher","first-page":"676","DOI":"10.1161\/ATVBAHA.113.302677","article-title":"Efficacy and safety of ETC-1002, a novel investigational low-density lipoprotein-cholesterol-lowering therapy for the treatment of patients with hypercholesterolemia and type 2 diabetes mellitus.","volume":"34","author":"Gutierrez","year":"2014","journal-title":"Arterioscler Thromb Vasc Biol."},{"key":"B29","doi-asserted-by":"publisher","first-page":"568","DOI":"10.1016\/j.jacl.2019.05.003","article-title":"Complementary low-density lipoprotein-cholesterol lowering and pharmacokinetics of adding bempedoic acid (ETC-1002) to high-dose atorvastatin background therapy in hypercholesterolemic patients: a randomized placebo-controlled trial.","volume":"13","author":"Lalwani","year":"2019","journal-title":"J Clin Lipidol."},{"key":"B30","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1016\/j.atherosclerosis.2020.12.023","article-title":"Combination of bempedoic acid, ezetimibe, and atorvastatin in patients with hypercholesterolemia: a randomized clinical trial.","volume":"320","author":"Rubino","year":"2021","journal-title":"Atherosclerosis."},{"key":"B31","doi-asserted-by":"publisher","first-page":"593","DOI":"10.1016\/j.jacl.2021.05.002","article-title":"Lipid lowering with bempedoic acid added to a proprotein convertase subtilisin\/kexin type 9 inhibitor therapy: a randomized, controlled trial.","volume":"15","author":"Rubino","year":"2021","journal-title":"J Clin Lipidol."},{"key":"B32","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1007\/s40264-020-00931-6","article-title":"Effect of bempedoic acid on serum uric acid and related outcomes: a systematic review and meta-analysis of the available phase 2 and phase 3 clinical studies.","volume":"43","author":"Cicero","year":"2020","journal-title":"Drug Saf."},{"key":"B33","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1186\/s13059-018-1439-8","article-title":"Hepatic steatosis risk is partly driven by increased de novo lipogenesis following carbohydrate consumption.","volume":"19","author":"Sanders","year":"2018","journal-title":"Genome Biol."},{"key":"B34","doi-asserted-by":"publisher","first-page":"100051","DOI":"10.1016\/j.crphar.2021.100051","article-title":"ATP citrate lyase inhibitor Bempedoic Acid alleviate long term HFD induced NASH through improvement in glycemic control, reduction of hepatic triglycerides & total cholesterol, modulation of inflammatory & fibrotic genes and improvement in NAS score.","volume":"2","author":"Sanjay","year":"2021","journal-title":"Curr Res Pharmacol Drug Discov."},{"key":"B35","doi-asserted-by":"publisher","first-page":"829","DOI":"10.1172\/JCI34275","article-title":"Contribution of de novo fatty acid synthesis to hepatic steatosis and insulin resistance: lessons from genetically engineered mice.","volume":"118","author":"Postic","year":"2008","journal-title":"J Clin Invest."},{"key":"B36","doi-asserted-by":"publisher","first-page":"879355","DOI":"10.3389\/fcvm.2022.879355","article-title":"Updated understanding of the crosstalk between glucose\/insulin and cholesterol metabolism.","volume":"9","author":"Xiao","year":"2022","journal-title":"Front Cardiovasc Med."},{"key":"B37","doi-asserted-by":"publisher","first-page":"868","DOI":"10.1111\/dom.14645","article-title":"Bempedoic acid in patients with type 2 diabetes mellitus, prediabetes, and normoglycaemia: a post hoc analysis of efficacy and glycaemic control using pooled data from phase 3 clinical trials.","volume":"24","author":"Leiter","year":"2022","journal-title":"Diabetes Obes Metab."},{"key":"B38","doi-asserted-by":"publisher","first-page":"e048893","DOI":"10.1136\/bmjopen-2021-048893","article-title":"Clinical efficacy and safety outcomes of bempedoic acid for LDL-C lowering therapy in patients at high cardiovascular risk: a systematic review and meta-analysis.","volume":"12","author":"Lin","year":"2022","journal-title":"BMJ Open."},{"key":"B39","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1016\/j.rceng.2021.11.003","article-title":"Bempedoic acid in patients with type 2 diabetes.","volume":"222","author":"Masson","year":"2022","journal-title":"Rev Clin Esp."},{"key":"B40","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1186\/s12933-020-01101-9","article-title":"Efficacy and safety of bempedoic acid for prevention of cardiovascular events and diabetes: a systematic review and meta-analysis.","volume":"19","author":"Wang","year":"2020","journal-title":"Cardiovasc Diabetol."},{"key":"B41","doi-asserted-by":"publisher","first-page":"1119","DOI":"10.1056\/NEJMoa1707914","article-title":"Antiinflammatory therapy with canakinumab for atherosclerotic disease.","volume":"377","author":"Ridker","year":"2017","journal-title":"N Engl J Med."},{"key":"B42","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1016\/S0140-6736(17)32814-3","article-title":"Relationship of C-reactive protein reduction to cardiovascular event reduction following treatment with canakinumab: a secondary analysis from the CANTOS randomised controlled trial.","volume":"391","author":"Ridker","year":"2018","journal-title":"Lancet."},{"key":"B43","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1080\/07853890.2018.1498118","article-title":"Lipid lowering drugs and inflammatory changes: an impact on cardiovascular outcomes?","volume":"50","author":"Ruscica","year":"2018","journal-title":"Ann Med."},{"key":"B44","doi-asserted-by":"publisher","first-page":"853","DOI":"10.1007\/s10557-021-07147-5","article-title":"Role of bempedoic acid in clinical practice.","volume":"35","author":"Ballantyne","year":"2021","journal-title":"Cardiovasc Drugs Ther."},{"key":"B45","doi-asserted-by":"publisher","first-page":"1178","DOI":"10.1161\/ATVBAHA.117.310676","article-title":"Bempedoic acid lowers low-density lipoprotein cholesterol and attenuates atherosclerosis in low-density lipoprotein receptor-deficient (LDLR(+\/\u2013) and LDLR(\u2013\/\u2013)) yucatan miniature pigs.","volume":"38","author":"Burke","year":"2018","journal-title":"Arterioscler Thromb Vasc Biol."},{"key":"B46","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1016\/j.atherosclerosis.2018.06.002","article-title":"Efficacy and safety of bempedoic acid added to ezetimibe in statin-intolerant patients with hypercholesterolemia: a randomized, placebo-controlled study.","volume":"277","author":"Ballantyne","year":"2018","journal-title":"Atherosclerosis."},{"key":"B47","doi-asserted-by":"publisher","first-page":"1780","DOI":"10.1001\/jama.2019.16585","article-title":"Effect of bempedoic acid vs placebo added to maximally tolerated statins on low-density lipoprotein cholesterol in patients at high risk for cardiovascular disease: the CLEAR wisdom randomized clinical trial.","volume":"322","author":"Goldberg","year":"2019","journal-title":"JAMA."},{"key":"B48","doi-asserted-by":"publisher","first-page":"1022","DOI":"10.1056\/NEJMoa1803917","article-title":"Safety and efficacy of bempedoic acid to reduce LDL cholesterol.","volume":"380","author":"Ray","year":"2019","journal-title":"N Engl J Med."},{"key":"B49","doi-asserted-by":"publisher","first-page":"e011662","DOI":"10.1161\/JAHA.118.011662","article-title":"Efficacy and safety of bempedoic acid in patients with hypercholesterolemia and statin intolerance.","volume":"8","author":"Laufs","year":"2019","journal-title":"J Am Heart Assoc."},{"key":"B50","doi-asserted-by":"publisher","first-page":"649","DOI":"10.1016\/j.jacl.2020.08.009","article-title":"Bempedoic acid safety analysis: pooled data from four phase 3 clinical trials.","volume":"14","author":"Bays","year":"2020","journal-title":"J Clin Lipidol."},{"key":"B51","doi-asserted-by":"publisher","first-page":"1124","DOI":"10.1001\/jamacardio.2020.2314","article-title":"Association of bempedoic acid administration with atherogenic lipid levels in phase 3 randomized clinical trials of patients with hypercholesterolemia.","volume":"5","author":"Banach","year":"2020","journal-title":"JAMA Cardiol."},{"key":"B52","doi-asserted-by":"publisher","first-page":"498","DOI":"10.1248\/bpb.33.498","article-title":"Renal secretion of uric acid by organic anion transporter 2 (OAT2\/SLC22A7) in human.","volume":"33","author":"Sato","year":"2010","journal-title":"Biol Pharm Bull."},{"key":"B53","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1016\/j.dmpk.2019.02.006","article-title":"Estimation of changes in serum creatinine and creatinine clearance caused by renal transporter inhibition in healthy subjects.","volume":"34","author":"Nakada","year":"2019","journal-title":"Drug Metab Pharmacokinet."},{"key":"B54","doi-asserted-by":"publisher","first-page":"593","DOI":"10.1177\/2047487319864671","article-title":"Bempedoic acid plus ezetimibe fixed-dose combination in patients with hypercholesterolemia and high CVD risk treated with maximally tolerated statin therapy.","volume":"27","author":"Ballantyne","year":"2020","journal-title":"Eur J Prev Cardiol."},{"key":"B55","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1016\/j.ahj.2020.10.060","article-title":"Rationale and design of the CLEAR-outcomes trial: evaluating the effect of bempedoic acid on cardiovascular events in patients with statin intolerance.","volume":"235","author":"Nicholls","year":"2021","journal-title":"Am Heart J."},{"key":"B56","doi-asserted-by":"publisher","first-page":"1031","DOI":"10.1080\/17425255.2021.1951222","article-title":"Evaluating pharmacokinetics of bempedoic acid in the treatment of hypercholesterolemia.","volume":"17","author":"Cicero","year":"2021","journal-title":"Expert Opin Drug Metab Toxicol."},{"key":"B57","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/j.numecd.2021.09.023","article-title":"Clinical evaluation of bempedoic acid for the treatment of hyperlipidaemia.","volume":"32","author":"Averna","year":"2022","journal-title":"."},{"key":"B58","doi-asserted-by":"publisher","first-page":"789","DOI":"10.1111\/cts.13202","article-title":"Pharmacokinetics of bempedoic acid in patients with renal impairment.","volume":"15","author":"Amore","year":"2022","journal-title":"Clin Transl Sci."}],"container-title":["Frontiers in Cardiovascular Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fcvm.2022.1028355\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,10,28]],"date-time":"2022-10-28T02:02:29Z","timestamp":1666922549000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fcvm.2022.1028355\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,10,28]]},"references-count":58,"alternative-id":["10.3389\/fcvm.2022.1028355"],"URL":"https:\/\/doi.org\/10.3389\/fcvm.2022.1028355","relation":{},"ISSN":["2297-055X"],"issn-type":[{"value":"2297-055X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,10,28]]},"article-number":"1028355"}}